01122nas a2200397   4500000000100000000000100001008004100002653001000043653001100053653001100064653000900075653002600084653004200110653003000152653005400182653001700236653001500253653003900268653001200307653002000319653001000339653002100349653004900370100001300419700001500432700001900447700001700466700001900483700001600502700001700518245014200535250001500677300001000692490000800702020001400710       2024                            d10aAdult10aHumans10aFemale10aMale10aRetrospective Studies10aAnti-Bacterial Agents/therapeutic use10a*Clostridioides difficile10a*Clostridium Infections/drug therapy/epidemiology10aRisk Factors10arecurrence10aClostridioides difficile infection10aEngland10aEpidemiological10aRecur10aReal-world study10aRecurrent clostridioides difficile infection1 aS. Ghosh1 aA. Antunes1 aH. Rinta-Kokko1 aE. Chaparova1 aS. Lay-Flurrie1 aA. Tricotel1 aF. Andersson00aClostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015 to 2019: The RECUR England study  a2024/01/08  a31-380 v140  a1201-9712